We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Stroke Genetics Study Triples Number of Known Risk Loci

By LabMedica International staff writers
Posted on 11 Apr 2018
Results of one of the largest genome-wide-association studies (GWAS) to be carried out on stroke revealed 22 new stroke risk loci, bringing the total to 32, which more than triples the number of gene regions known to affect stroke risk.

The study was conducted under the auspices of MEGASTROKE, a project of the International Stroke Genetics Consortium, a multi-disciplinary collaborative of experts in stroke genetics. More...
MEGASTROKE members include research groups from the United States, Germany, France, the United Kingdom, Japan, Iceland, Spain, Switzerland, Italy, Belgium, the Netherlands, Denmark, Sweden, Norway, Finland, Estonia, Poland, Singapore, Australia, and Canada.

In the current study, 521,612 DNA samples (from 67,162 cases and 454,450 controls) provided by individuals from Europe, North and South America, Asia, Africa, and Australia were analyzed. In addition, data from 29 other large genetic studies were incorporated for analysis.

Results published in the March 12, 2018, online edition of the journal Nature Genetics revealed 22 new stroke risk loci. In addition, the investigators found shared genetic variation with related vascular traits, including blood pressure, cardiac traits, and venous thromboembolism at 18 individual loci. Eleven new susceptibility loci indicated mechanisms not previously implicated in stroke pathophysiology, and several of the implicated genes were considered to be potential new drug targets for stroke treatment and prevention.

"This study really advances what we know about the genetics of stroke," said contributing author Dr. Steven Kittner, professor of neurology at the University of Maryland School of Medicine (Baltimore, USA). "With this new information we can help researchers work to develop new treatments and new therapies."

"These findings, which link stroke with multiple other diseases, and with dysregulation of genes, proteins, and molecular pathways in specific cell types and organs, were generated using novel bioinformatics approaches that use information from many international biological databases. This work underscores the vital importance of data sharing," said contributing author Dr. Braxton Mitchell, professor of medicine at the University of Maryland School of Medicine.

Related Links:
International Stroke Genetics Consortium
University of Maryland School of Medicine


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.